Showing results (1411-1420 of 1,437) with videos related to
Sort By:
Pageof 144
Cancer Cell|November 12, 2024
In vivo models of subclonal oncogenesis and dependency in hematopoietic malignancyRobert L Bowman, Andrew J Dunbar, Tanmay Mishra, et al.Cancer Discovery|January 17, 2024
Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative NeoplasmsAndrew J Dunbar, Robert L Bowman, Young C Park, et al.Blood Advances|October 23, 2023
A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AMLSheng F Cai, Ying Huang, Jennie R Lance, et al.Nature|June 1, 2018
Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cellsJoseph A Fraietta, Christopher L Nobles, Morgan A Sammons, et al.Nature Biomedical Engineering|March 10, 2026
Predictive biomarkers of response to chimeric antigen receptor (CAR) T-cell therapy for pan-haematologic cancerGregory M Chen, Ankita Jain, David T Gering, et al.Cancer Cell|July 19, 2016
Mutant IDH1 Downregulates ATM and Alters DNA Repair and Sensitivity to DNA Damage Independent of TET2Satoshi Inoue, Wanda Y Li, Alan Tseng, et al.Cancer|April 20, 2023
Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master TrialVu H Duong, Amy S Ruppert, Alice S Mims, et al.American Journal of Hematology|October 17, 2022
Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemiaMaximilian Stahl, Andriy Derkach, Noushin Farnoud, et al.The New England Journal of Medicine|September 10, 2015
Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell LeukemiaEnrico Tiacci, Jae H Park, Luca De Carolis, et al.Nature Genetics|July 15, 2025
Germline genetic variation impacts clonal hematopoiesis landscape and progression to malignancyJie Liu, Duc Tran, Liying Xue, et al.Pageof 144